Diagnosis and clinical characteristics of inherited activated protein c resistance

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 315-330

  Samama, M M ^a   Simon, D ^a   Horellou, M H ^a   Trossaert M ^a   Elalamy, I ^a   Conard, J ^a  

^a HÔTEL DIEU   (France)

Author keywords

Activated protein C resistance; Factor V Leiden; Pulmonary embolism; Superficial vein thrombosis; Thrombophilia; Venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

ACTIVATED PROTEIN C RESISTANCE; CLINICAL FEATURE; CONFERENCE PAPER; GENE MUTATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THROMBOPHILIA; VEIN THROMBOSIS;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; CONTRACEPTIVES, ORAL, HORMONAL; DNA MUTATIONAL ANALYSIS; ENZYME ACTIVATION; FACTOR V; FACTOR V DEFICIENCY; FEMALE; GENOTYPE; HUMANS; INTRACRANIAL EMBOLISM AND THROMBOSIS; MALE; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROTEIN C; PROTEIN S DEFICIENCY; PUERPERAL DISORDERS; PULMONARY EMBOLISM; RECURRENCE; RISK FACTORS; THROMBOPHLEBITIS;

EID: 0029908647     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217312     Document Type: Article

References (55)

1. Egcberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrhag 1965; 13: 516-530.
2. Comp PC. Jacobs RM, Ferrell GL, Esmon CT. Activation of protein C in vivo. J Clin Invest 1982; 70; 127-134.
3. Griffin JH. Evatt B, Zimmerman TS, kleis AJ. Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981: 68; 1370-1373.
4. Comp PC, Nixon RR. Cooper MR. Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 2082-2088.
5. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Purification and characterization of the lipo protein-associated coagulation inhibitor from human plasma. J Biol Chem 1989;264:18832-18837.
6. Dahlbäck B. Carlsson M, Svcnsson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sei USA 1993; 90: 1004-1008.
7. Dahlbäck B. Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sei USA 1994;81:1396-1400.
8. Bertina RM. Koeleman BPC, Koster T. Rosendaal FR. Dirven RJ. De Ronde H, Van Der Velden PA. Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
9. Dahlbäck B. Resistance to activated protein C, the Arg 506 to Gin mutation in the factor V gene and venous thrombosis. Functional tests and DNA-bascd assays, pros and cons. Thromb. Haemostas 1995; 73: 739-742.
10. Trossacrt M, Conard J, Horellou MH, Samaha M. Elalamy I, Samama M. Résistance à la protéine C activée dans les accidents thromboemboliques veineux. Fréquence et manifestations cliniques. Presse Med 1995; 24,4: 209-212.
11. Hopper WC, Dillcy A. Ribeiro MJA, Benson J, Austin H, Silva V. Rawlins P. Wenger NK. Evatt BL. A racial difference in the prevalence of the Arg 506-> Gin mutation. Thromb Res 1996; 81,5: 577-581.
12. Ozawa T, Niiya K, Sakuragawa N. Absence of factor V Leiden in the japanese. Thromb Res 1996: 81, 5: 595-596.
13. Chan C, Bourkc C, Lam CK. Liu HW, Brookes S, Jenkins V, Past J. Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors-Correlation with absence of Arg506-Gln mutation of factor V gene. Thromb Haemostas 1996:75 (3): 520-526.
14. Rccs DC. World distribution of factor V Leiden. Lancet 1995: 1133-1134
15. De Maat M PM. Kluft C, Jespersen J. Gram J. World distribution of factor V Leiden mutation. Lancet 1996, 347: 58 (letter).
16. Schröder W, Koessling M, Wulff K, Wehnert M. Hermann FH. World distribution of factor V Leiden mutation. Lancet 1996. 347: 58-59 (letter).
17. Fouere S, Guibal F. Morel P. World distribution of factor V Leiden mutation. Lancet 1996. 347: 59 (letter).
18. Gou D, Naipal A, Reitsma P.H.:World distribution of factor V Leiden mutation. Lancet 1996, 347, 59 (letter).
19. Samama MM, Trossaërt M, Horellou MH, Elalamy I, Conard J. Risk of thrombosis in patients homozygous for factor V Leiden. Blood 1995; 86, 15: 4700-4702.
20. Soria J, Soria C, Samama M. Dosage du plasminogène à l'aide d’un substrat chromogène tri peptidique. Path Biol 1976; 24: 725-729
21. Trossaërt M, Conard J. Horellou MH. Samama MM. Influence of storage conditions of activated protein C resistance. Thromb Haemostas 1995: 73: 163-164.
22. Samama M, Trossaërt M, Conard J, Horellou MH. Elalamy I, Samama MM. Prevalence and patient profile in activated protein C resistance. Am J Clin Pathol 1995; 104: 450-454.
23. Trossaërt M, Conard J. Horellou MH. Ireland H, Dayston TA, Lane DA. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344: 1709 (letter).
24. Trossaërt M, Conard J, Horellou MH, Elalamy I, Samama MM. The modified APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulant. Thromb Haemostas 1996; 75. 3: 520-526.
25. Jorquera JL, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-1163.
26. Denson KWE, Reed SV, Haddon ME. The modified APC resistance test. Thromb Haemostas 1995.74(3): 995 (letter).
27. Galimore G, Thom J, Baker RI. Diagnosis of APC resistance in patients on standard or low molecular weight heparin. Thromb Haemostas 1996; 75 (2): 372-377.
28. Villa P, Aznar J, Jorquera JI, Casana P. Laboratory diagnosis of APC-resistance in patients with lupus anticoagulant. Thromb Haemostas 1995; 74 (6)1604-1612.
29. Horellou MH, Conard J, Trossaërt M, Elalamy I, Samama MM. Utilisation du test de Dahlback modifié pour le diagnostic de résistance à la protéine C activée (Pca) chez les patients porteurs d’un anticoagulant circulant de type lupus (LA): à propos de. 40 observations. Hémostase et Neurologie-Réunion du Groupe d’Etudes sur l’Hémostase et la Thrombose Paris, 1996. Faculté de Médecine Saint Louis-Lariboisière.
30. Horellou MH, Conard J, Arkam R, Trossaërt M, Elalamy I, Deschamps A. Samama MM. Facteur V Leiden homozygote chez 25 patients: expression clinique et marqueurs d’activation de la coagulation. Hematology and Cell Therapy. XVth Congress of the French Society of Hematology 1996; 38: 41 (abst 78).
31. Zôller V. Svensson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524.
32. Leroy-Matheron C, Lèvent M, Pignon JM, Mendonca C, Gouault-Heilman M. The 1691 G->A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients. Thromb Haemostas 1996; 75 (1): 4-10.
33. Denningcr MH. Beldjord K, Durand F, Dénié C, Valla D, Guillin MC. Budd-Chiari syndrome and factor V Leiden mutation. Lancet 1995; 345: 525-526.
34. Lcvoir D, Emmerich J. Alhenc-Gelas M, Dumontier I, Petite JP, Fiessinger JN, Aiach M. Portai vein thrombosis and factor V Arg 506 to Gin mutation. Thromb Haemostas 1995; 73; 550-551.
35. Mahmoud AEA, Wilde JT, Elias E. Budd-Chiari syndrome and factor V Leiden mutation. Lancet 1995: 345: 522.
36. Ferrer-Antunes C, Palmeiro A, Frazzao F. et al.-APC resistance in Portuguese Caucasian patients with deep venous thrombosis or retinal vein occlusion. Xvth Congress of the International Society on Thrombosis and Haemostasis 1995, Jérusalem p. 1370 (abst.).
37. Raguenes P. Mercier B, Escoffre M, Traoré L, Blouch MT. Robinet A, Abgrall JF, Fercc C. Et Le Getbo. Mutation 1691 G-> A du gène du facteur V: pas d'association avec les thromboses de la veine centrale de la rétine. Presse Med 1996; 25 (9): 460.
38. Halbmaycr WM, Haushofer A, Schon R, Fischer M. The prevalence of poor anticoagulant response to activated proteinC (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 1994; 5: 51-56.
39. Ridker PM, Hennekens CH, Lindpaintner K. Stampfcr MJ, Eisenberg PR. Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 322: 912-917.
40. Kontula K, Yliorkala A, Miettinen H. Vuorio A, Kauppinen-Makelin R, Hàmâlâinen L, Palomâki H, Kaste M. Arg 506 Gin factor C mutation (Factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemostas 1995; 73 (4): 558-560.
41. Emmerich J, Poirier C, Evans A, Marques-Vidal P, Arvciler D, Luc G, Aiach M. Cambien F. Myocardial infarction, Arg506 to Gin factor V mutation, and activated protein C resistance. Lancet 1995; 345: 321.
42. Ganesan V, Helsey H, Cookson J, Osbron A, Kirkham FJ. Activated protein C resistance in childhood stroke. Lancet 1996; 347: 260.
43. Rosendaal FR, Koster T, Vandenbroueke JP, Rcitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995: 85: 1504-1508.
44. Kocleman BPC. Reitsma PH, Allart CF, Bertina RM. Activated protein C resistance as an additionnai risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1035.
45. Zoller B. Bcmtsdotter A, Garcia De Frutas P, Dahlbiick B. Resistance to activated protein C as an additional genetic risk factor to hereditary deficiency of protein S. Blood 1995; 85: 3518-3523.
46. Ireland H. Bayston T. Thompson E, Adami A. Goncalves C, Lane DA. Barbui T. Apparent heterozygous type II protein C deficiency caused by the factor V 506 Arg to Gin mutation. Thromb Haemostas 1995; 73: 731-732.
47. Gandrille S. Greengard JS. Alhenc-Gelas M. Juhan-Vague I, Abgrall JF, Jude B. Griffin JH. Aiach M. And The French Network On The Behalf OÎINSHRM.-Incidence of activated protein C resistance caused by the Arg 506 Gin mutation in factor V in 113 unrelated symptomatic protein C deficient patients. Blood 1995; 86: 219-224.
48. Zoller B. Bernsdotter A, De Frutos PG. Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-3523.
49. Van Boven HH. Reitsma PH. Rosendaa! FR. Bayston TA, Chowdhury V, Bauer KA, Scharrer I, Conard J. Lane DA. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemostas 1996: 75 (3): 417-421.
50. Miletich JP. Prescott SM, White R. Majerus PW. Bovill EG. Inherited predisposition to thrombosis. Cell 1993; 72: 477-480.
51. Ridker PM, Hennekens CH, Lindpaintner K. Stampfer MJ. Eisenbcrg PR. Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917.
52. Vandenbroucke JP. Koster T, Briet E, Reitsma PH. Bettina RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
53. Cumming AM, Tait RC, Fildes S, Hay CRP. Diagnosis of APC resistance during pregnancy. Brit J Haematol 1996:92: 1026-1029.
54. Cumming AM, Tait RC, Fildes S. Yoong A, Keeney S. Hay CRM. Development of resistance to activated protein C during pregnancy. Brit J Haematol 1995; 90:725-727.
55. Bettina RM, Broekmans AW, Van Der Linden IK, Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemostas 1982; 48:1-5.